Related Experiment Video

Updated: Sep 28, 2026

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
06:18

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause

Published on: August 13, 2019

[Effect of hormone replacement therapy on homocysteine and echocardiography in postmenopausal women]

Ying Hui1, Yiyong Wu, Luyan Xiao

  • 1Department of Obstetrics and Gynecology, Beijing Hospital, Ministry of Public Health, Beijing 100730, China.

Zhonghua Fu Chan Ke Za Zhi
|December 19, 2002
PubMed

Insights

Short-term hormone replacement therapy (HRT) does not affect homocysteine levels in postmenopausal women. However, long-term HRT users show lower plasma homocysteine compared to non-users.

Area of Science:

  • Endocrinology
  • Cardiovascular Health
  • Metabolic Studies

Context:

  • Menopause is associated with hormonal changes impacting cardiovascular risk.
  • Elevated homocysteine levels are a potential risk factor for cardiovascular disease.
  • Hormone replacement therapy (HRT) is used to manage menopausal symptoms.

Purpose:

  • To investigate the impact of HRT on fasting total plasma homocysteine levels.
  • To assess the effects of HRT on echocardiographic parameters in postmenopausal women.

Summary:

  • A 3-month HRT regimen (conjugated equine estrogen with medroxyprogesterone acetate) did not alter fasting plasma homocysteine in postmenopausal women.
  • Postmenopausal women using HRT for 1.5 years exhibited significantly lower plasma homocysteine levels compared to those who never used HRT.
  • Echocardiography revealed no significant differences between long-term HRT users and non-users.

Impact:

  • Short-term HRT does not appear to influence homocysteine levels.
  • Long-term HRT use may be associated with reduced homocysteine levels.
  • HRT does not seem to affect cardiac structure or function as assessed by echocardiography in the long term.
Abstract

More Related Videos

Exploring Independent Effects of Follicle-Stimulating Hormone In Vivo in a Mouse Model05:32

Exploring Independent Effects of Follicle-Stimulating Hormone In Vivo in a Mouse Model

Published on: August 11, 2023

Related Concept Videos

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Imaging Studies for Cardiovascular System I:Echocardiography01:17

Imaging Studies for Cardiovascular System I:Echocardiography

Cardiac imaging studies encompass a wide range of noninvasive and minimally invasive techniques designed to visualize the heart's structure and function in detail. One such technique is echocardiography, which uses high-frequency ultrasound waves to produce detailed images of the heart, known as echocardiograms.
Indications: Echocardiography is utilized to diagnose heart failure, valve disorders, and myocardial infarction. It also assesses cardiac structures' size, shape, and motion, evaluates...
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Mitral Valve Prolapse II: Assessment and Management01:22

Mitral Valve Prolapse II: Assessment and Management

IntroductionA range of clinical features characterizes Mitral Valve Prolapse (MVP), but it is important to note that many individuals with MVP are asymptomatic and may remain so throughout their lives. For those who do exhibit symptoms, the following are the key clinical features:Palpitations: This is a common symptom where individuals feel an irregular or rapid heartbeat. Palpitations in MVP are often due to arrhythmias such as premature ventricular contractions or supraventricular tachycardia.
Menopause01:28

Menopause

Menopause, a natural biological process marking the end of a woman's fertility, typically occurs between the fifth and sixth decade of life. This phase is characterized by the exhaustion of the ovarian follicle pool, leading to less responsive ovaries despite the high levels of Follicle Stimulating Hormone (FSH) and Luteinizing Hormone (LH). The consequential decrease in estrogen production results in symptoms like hot flashes, heavy sweating, headaches, hair loss, muscle pains, vaginal...